Hypofractionated radiation in secretory breast cancer: A case report.
Ken TatebeClaudia PerezLydia UshaRitu GhaiDian WangParul BarryPublished in: Rare tumors (2021)
Secretory carcinoma is a rare and indolent breast cancer with a lack of established treatment paradigms. We describe a case of a woman who underwent breast conservative therapy in the modern era. A 48 year old woman with a screen-detected left breast cancer was found to have early-stage secretory carcinoma after definitive breast conservation surgery. Further management with adjuvant radiation was recommended. After definitive breast conservative surgery, final pathology was notable for secretory breast carcinoma due to the immunohistologic characteristics of the tumor, ETV6-NTRK3 gene fusion, and histologic findings. After multi-disciplinary discussion, it was recommended that the patient proceed with adjuvant radiation. She was treated using a modestly hypofractionated regimen of 4256 cGy in 16 fractions. She tolerated the treatment well, developing only grade 1 radiation dermatitis. At 1 year follow-up she was clinically and radiographically free of disease. With a shift in management toward breast conservative therapy, defining the role of adjuvant radiation for secretory carcinomas in the modern era is of increasing importance. Modestly hypofractionated radiation is well-tolerated. Oncologic outcomes will be assessed with continued long-term follow-up.
Keyphrases
- early stage
- radiation therapy
- radiation induced
- minimally invasive
- coronary artery bypass
- stem cells
- type diabetes
- case report
- acute lymphoblastic leukemia
- prostate cancer
- squamous cell carcinoma
- small cell lung cancer
- acute coronary syndrome
- adipose tissue
- transcription factor
- rectal cancer
- percutaneous coronary intervention
- combination therapy
- weight loss
- brain metastases
- cell therapy
- childhood cancer
- hodgkin lymphoma
- radical prostatectomy